R Clèries1,2, R M Rooney3, M Vilardell4, J A Espinàs5, T Dyba3, J M Borras5,6. 1. Catalan Cancer Plan, IDIBELL, Hospital Duran i Reynals, Av. Gran Via de l'Hospitalet, 199-203-1a planta, L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. r.cleries@iconcologia.net. 2. Department of Clinical Sciences, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. r.cleries@iconcologia.net. 3. European Commission, DG Joint Research Centre, Institute for Health and Consumer Protection, Public Health-Cancer Policy Support, 21020, Ispra, Varese, Italy. 4. Section Statistics from the Department of Genetics, Microbiology and Statistics, Biology Faculty, University of Barcelona, 08028, Barcelona, Spain. 5. Catalan Cancer Plan, IDIBELL, Hospital Duran i Reynals, Av. Gran Via de l'Hospitalet, 199-203-1a planta, L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. 6. Department of Clinical Sciences, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Abstract
BACKGROUND: We assessed differences in predicted breast cancer (BC) mortality rates, across Europe, by 2020, taking into account changes in the time trends of BC mortality rates during the period 2000-2010. METHODS: BC mortality data, for 27 European Union (EU) countries, were extracted from the World Health Organization mortality database. First, we compared BC mortality data between time periods 2000-2004 and 2006-2010 through standardized mortality ratios (SMRs) and carrying out a graphical assessment of the age-specific rates. Second, making use of the base period 2006-2012, we predicted BC mortality rates by 2020. Finally, making use of the SMRs and the predicted data, we identified a clustering of countries, assessing differences in the time trends between the areas defined in this clustering. RESULTS: The clustering approach identified two clusters of countries: the first cluster were countries where BC predicted mortality rates, in 2020, might slightly increase among women aged 69 and older compared with 2010 [Greece (SMR 1.01), Croatia (SMR 1.02), Latvia (SMR 1.15), Poland (SMR 1.14), Estonia (SMR 1.16), Bulgaria (SMR 1.13), Lithuania (SMR 1.03), Romania (SMR 1.13) and Slovakia (SMR 1.06)]. The second cluster was those countries where BC mortality rates level off or decrease in all age groups (remaining countries). However, BC mortality rates between these clusters might diminish and converge to similar figures by 2020. CONCLUSIONS: For the year 2020, our predictions have shown a converging pattern of BC mortality rates between European regions. Reducing disparities, in access to screening and treatment, could have a substantial effect in countries where a non-decreasing trend in age-specific BC mortality rates has been predicted.
BACKGROUND: We assessed differences in predicted breast cancer (BC) mortality rates, across Europe, by 2020, taking into account changes in the time trends of BC mortality rates during the period 2000-2010. METHODS: BC mortality data, for 27 European Union (EU) countries, were extracted from the World Health Organization mortality database. First, we compared BC mortality data between time periods 2000-2004 and 2006-2010 through standardized mortality ratios (SMRs) and carrying out a graphical assessment of the age-specific rates. Second, making use of the base period 2006-2012, we predicted BC mortality rates by 2020. Finally, making use of the SMRs and the predicted data, we identified a clustering of countries, assessing differences in the time trends between the areas defined in this clustering. RESULTS: The clustering approach identified two clusters of countries: the first cluster were countries where BC predicted mortality rates, in 2020, might slightly increase among women aged 69 and older compared with 2010 [Greece (SMR 1.01), Croatia (SMR 1.02), Latvia (SMR 1.15), Poland (SMR 1.14), Estonia (SMR 1.16), Bulgaria (SMR 1.13), Lithuania (SMR 1.03), Romania (SMR 1.13) and Slovakia (SMR 1.06)]. The second cluster was those countries where BC mortality rates level off or decrease in all age groups (remaining countries). However, BC mortality rates between these clusters might diminish and converge to similar figures by 2020. CONCLUSIONS: For the year 2020, our predictions have shown a converging pattern of BC mortality rates between European regions. Reducing disparities, in access to screening and treatment, could have a substantial effect in countries where a non-decreasing trend in age-specific BC mortality rates has been predicted.
Entities:
Keywords:
Breast cancer; Europe; Mortality; Projections; Screening; Time trends
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: Sue M Moss; Christopher Wale; Robert Smith; Andrew Evans; Howard Cuckle; Stephen W Duffy Journal: Lancet Oncol Date: 2015-07-20 Impact factor: 41.316
Authors: Montserrat Martinez-Alonso; Ester Vilaprinyo; Rafael Marcos-Gragera; Montserrat Rue Journal: Breast Cancer Res Date: 2010-08-03 Impact factor: 6.466
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Tit Albreht; Martin McKee; Delia-Marina Alexe; Michel P Coleman; Jose M Martin-Moreno Journal: Eur J Cancer Date: 2008-03-18 Impact factor: 9.162
Authors: Nathalie J Massat; Amanda Dibden; Dharmishta Parmar; Jack Cuzick; Peter D Sasieni; Stephen W Duffy Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-08 Impact factor: 4.254
Authors: R Clèries; A Ameijide; M Buxó; J M Martínez; R Marcos-Gragera; M-L Vilardell; M Carulla; Y Yasui; M Vilardell; J A Espinàs; J M Borràs; J Galceran; À Izquierdo Journal: Clin Transl Oncol Date: 2018-03-06 Impact factor: 3.405
Authors: Laura Ciria-Suarez; Paula Jiménez-Fonseca; María Palacín-Lois; Mónica Antoñanzas-Basa; Ana Férnández-Montes; Aranzazu Manzano-Fernández; Beatriz Castelo; Elena Asensio-Martínez; Susana Hernando-Polo; Caterina Calderon Journal: PLoS One Date: 2020-12-21 Impact factor: 3.240